Clinical Trial Update: Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating benralizumab 30 mg SC as add-on therapy in uncontrolled eosinophilic asthma patients on medium-dose ICS-LABA, compared with conventiona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Eosinophilic Asthma | Phase 3 | Status: RECRUITING